Thorne HealthTech

Thorne HealthTech, Inc. is engaged in the provision of a total system for wellness. It utilizes testing and data to create improved product quality and deliver personalized solutions to consumers, health professionals, and professional sports teams. It also helps pharmaceutical and biotechnology companies repurpose existing drugs and compounds, improve existing medications and develop new products. The company was founded by Paul Jacobson in 2010 and is headquartered in New York, NY.

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Acquisition of PreCon strengthens brain health portfolio and provides access to world-class scientific advisory board NEW YORK , Feb. 3, 2023 /PRNewswire/ -- Thorne HealthTech, Inc. ("Thorne" or "Thorne HealthTech") (NASDAQ: THRN), a leader in developing innovative solutions for a personalized approach to health and wellness, today announced it has acquired all of the outstanding stock of PreCon Health, Inc. ("PreCon"), a company focused on scientific discovery, innovation, and advancing safe and effective products that support healthy brain function. The acquisition was completed on January 31, 2023, for an aggregate purchase price of $5.0 million.

THORNE HEALTHTECH ACQUIRES PRECON HEALTH

Thorne HealthTech continues to face lower revenue growth due to macro uncertainty. Management prefers to temporarily sacrifice the gross margin, but increase brand awareness.

Thorne HealthTech: Strong Fundamental Potential But Cost Pressure Remains

NEW YORK , Jan. 9, 2023 /PRNewswire/ -- On January 3, 2023, the U.S. Circuit Court of Appeals for the Federal Circuit in Washington, D.C., issued a final ruling rendering the previously issued U.S. Patent No.

U.S. Appeals Court Issues Final Ruling That Upholds Thorne HealthTech Inc.'s Prior Challenge of Nicotinamide Riboside Intellectual Property Claim

NEW YORK , Nov. 16, 2022 /PRNewswire/ -- Thorne HealthTech, Inc. ("Thorne HealthTech" or "the Company") (NASDAQ: THRN), a leader in developing personalized, innovative solutions to live healthier lives longer, today announced it will participate in a fireside chat and also meet with investors at the upcoming Evercore ISI HEALTHCONx Conference. A live webcast and replay of the fireside chat will be available on Wednesday, November 30, at 1:50 p.m.

Thorne HealthTech to Participate in Evercore ISI HEALTHCONx Conference

Thorne HealthTech, Inc. (NASDAQ:THRN ) Q3 2022 Earnings Conference Call November 10, 2022 8:00 AM ET Company Participants Thomas Wilson - Vice President, Investor Relations Paul Jacobson - Chief Executive Officer Bryan Conley - Chief Financial Officer Michelle Crow - Chief Marketing Officer Conference Call Participants Elizabeth Anderson - Evercore Sean Dodge - RBC Capital Markets Max Rakhlenko - Cowen and Co. Operator Welcome to the Thorne HealthTech Third Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode.

Thorne HealthTech, Inc. (THRN) Q3 2022 Earnings Call Transcript

Updates Full-Year 2022 Guidance NEW YORK , Nov. 9, 2022 /PRNewswire/ -- Thorne HealthTech, Inc. ("Thorne HealthTech", "Thorne" or the "Company") (NASDAQ: THRN), a leader in developing personalized, innovative solutions that empower individuals to live healthier, longer lives, today announced its financial results for the third quarter ended September 30, 2022. Third Quarter Highlights: Net sales grew 21.7% year-over-year to $58.4 million, with direct-to-consumer ("DTC") sales growth of 47.2% Gross profit grew 10.3% year-over-year to $28.2 million; gross margin decreased 500 basis points year-over-year to 48.2% Net income attributable to common stockholders grew to $3.7 million; adjusted EBITDA grew to $8.3 million Diluted earnings per share ("EPS") of $0.07; adjusted diluted EPS of $0.12 "People trust Thorne to support their daily wellness journeys because of the personalization we offer, the science behind our portfolio of solutions including our health tests and supplements, and our unmatched quality standards," said Paul Jacobson, Thorne HealthTech's chairman and CEO.

Thorne HealthTech Reports Third Quarter 2022 Results

NEW YORK , Oct. 25, 2022 /PRNewswire/ -- Thorne HealthTech, Inc. ("Thorne HealthTech" or "Thorne") (NASDAQ: THRN), a leader in developing innovative solutions for a personalized approach to health and wellness, announced today that it is collaborating with GenTegra, an innovator and leader of complete biological sample protection, to utilize GenTegra's patented Active Chemical Protection™ technology and Thorne's OneDraw™ collection device to develop a whole blood DNA collection cartridge and a complete stabilization and extraction kit. The collaboration paves the way for Thorne and GenTegra to introduce a product that will be inclusive of Thorne's OneDraw DNA cartridges and GenTegra's GenSolve technology for highly efficient DNA extraction.

THORNE HEALTHTECH AND GENTEGRA COLLABORATE TO DEVELOP A NEXT-GENERATION WHOLE BLOOD DNA COLLECTION AND EXTRACTION KIT

NEW YORK , Oct. 18, 2022 /PRNewswire/ -- Thorne HealthTech, Inc. (NASDAQ:  THRN ), a leader in developing innovative solutions for a personalized approach to health and wellness, will release its third quarter 2022 financial results after market close on Wednesday, Nov. 09, 2022. The company will host a conference call to discuss its results on Thursday, Nov. 10, 2022, at 8 a.m.

Thorne HealthTech Announces Third Quarter 2022 Earnings Release Date and Conference Call

Multi-year collaboration to introduce top athletes and casual gamers alike to science-driven products that support enhanced performance and a healthy lifestyle NEW YORK , Sept. 29, 2022 /PRNewswire/ -- Thorne HealthTech ("Thorne") (NASDAQ: THRN), the leader in developing innovative solutions for a personalized approach to health and wellness and Team Liquid, a leading worldwide professional esports organization, today announced that Thorne is now the official Health and Wellness Partner of Team Liquid.

THORNE AND TEAM LIQUID ANNOUNCE PARTNERSHIP BRINGING INNOVATIVE HEALTH AND WELLNESS SOLUTIONS TO THE ESPORTS COMMUNITY

Thorne HealthTech went public in September 2021, raising approximately $70 million in a U.S. IPO. The company designs and sells wellness and nutraceutical products worldwide.

Thorne HealthTech Grows But Faces Macro Headwinds

NEW YORK , Aug. 23, 2022 /PRNewswire/ -- Thorne HealthTech, Inc. ("Thorne HealthTech" or "Thorne") (NASDAQ: THRN), a leader in developing innovative solutions for a personalized approach to health and wellness and majority owner of Drawbridge Health announced today that its OneDraw™ Blood Collection Device has been certified in Japan as a medical device, having been cleared by the Pharmaceutical and Medical Devices Agency (PMDA). "This is a major victory for the OneDraw device because the PMDA has notoriously stringent qualifications to clear a device," said Paul Jacobson, CEO of Thorne HealthTech.

Thorne HealthTech's OneDraw™ Blood Collection Device Receives PMDA Certification in Japan

Thorne HealthTech, Inc. (NASDAQ:THRN ) Q2 2022 Earnings Conference Call August 10, 2022 8:00 AM ET Company Participants Thomas Wilson - Vice President, Investor Relations Paul Jacobson - Chief Executive Officer Bryan Conley - Chief Financial Officer Michelle Crow - Chief Marketing Officer Conference Call Participants Sean Dodge - RBC Capital Markets Oliver Chen - Cowen and Company Operator Hello and welcome to today's Thorne HealthTech Second Quarter 2022 Earnings Call. My name is Bailey, and I will be your moderator for today's call.

Thorne HealthTech, Inc. (THRN) CEO Paul Jacobson on Q2 2022 Results - Earnings Call Transcript

Revises Full-Year 2022 Guidance NEW YORK , Aug. 9, 2022 /PRNewswire/ -- Thorne HealthTech, Inc. ("Thorne HealthTech", "Thorne" or the "Company") (NASDAQ: THRN), a leader in developing personalized, innovative solutions to help people live healthier, longer lives, today announced its financial results for the second quarter ended June 30, 2022. Second Quarter Highlights: Net sales grew 30.7% year-over-year to $56.1 million, with direct-to-consumer (DTC) sales growth of 69.6% Gross profit grew 37.0% year-over-year to $31.4 million; gross margin increased 260 basis points year over year to 55.9% Net loss attributable to common stockholders of $5.6 million; adjusted EBITDA loss of $1.4 million Diluted loss per share of $0.11; adjusted diluted loss per share of $0.05 Revised full-year 2022 guidance for projected net sales of $235 million to $242 million; adjusted EBITDA of $28 million to $32 million; and adjusted earnings per share (EPS) of $0.36 to $0.39; previously issued guidance for projected gross margin of 53% to 55% reaffirmed "I am pleased to report record quarterly net sales, which grew 30.7% over the second quarter of last year, with continued gross margin expansion to 55.9% for the quarter," said Paul Jacobson, Thorne HealthTech's chairman and CEO.

Thorne HealthTech Reports Second Quarter 2022 Results

NEW YORK , Aug. 4, 2022 /PRNewswire/ -- Thorne HealthTech, Inc. ("Thorne HealthTech" or "Thorne") (NASDAQ: THRN), a leader in developing innovative solutions for a personalized approach to health and wellness, today announced a two-year continuation of the collaboration with AstraZeneca, a leading biopharmaceuticals company. The extended collaboration will see the internalization of Thorne's disease discovery platform into AZ for further evaluation and to gain insight into additional uses for AZ molecules.

Thorne HealthTech Announces Two-Year Collaboration with AstraZeneca on Disease Discovery System to Advance Novel Drug Discovery

NEW YORK , July 19, 2022 /PRNewswire/ -- Thorne HealthTech, Inc. ("Thorne HealthTech" or "Thorne") (NASDAQ: THRN), a leader in developing innovative solutions for a personalized approach to health and wellness, today announced that it has achieved self-affirmed GRAS (Generally Recognized as Safe) status for its proprietary nicotinamide riboside malate (NRM) product. Under the Federal Food, Drug and Cosmetic Act, GRAS is a regulatory classification term used to identify a food ingredient that is generally recognized among qualified experts as having been adequately shown to be safe under the conditions of its intended use.

Thorne HealthTech Achieves Self-Affirmed GRAS Status for Nicotinamide Riboside Malate

NEW YORK , July 19, 2022 /PRNewswire/ -- Thorne HealthTech, Inc. (NASDAQ: THRN), a leader in developing innovative solutions for a personalized approach to health and wellness, will release its second quarter 2022 financial results after the market close on Tuesday. Aug. 09, 2022.

Thorne HealthTech Announces Second Quarter 2022 Earnings Release Date and Conference Call

NEW YORK , June 13, 2022 /PRNewswire/ -- USRowing is pleased to announce that Thorne HealthTech (NASDAQ: THRN) has signed on as an Official USRowing Partner and the Exclusive Supplement Supplier for the U.S. National Team for 2022, 2023, and 2024. "We are so pleased to sign on Thorne as the Exclusive Supplement Provider for the U.S. National Team," said USRowing CEO, Amanda Kraus.

Thorne HealthTech partners with USRowing to Support the U.S. National Rowing Team

Nutraceutical companies will perform well during the next decade, even during a recession. DIY health trends are on the rise.

Thorne HealthTech: Poised To Outperform Other Nutraceutical Companies

Thorne's innovative approach to microbiome testing through a one-of-a-kind, user friendly wipe provides users with cutting-edge analysis and personalized results, changing the landscape of at-home gut health testing NEW YORK , May 24, 2022 /PRNewswire/ -- Thorne HealthTech, Inc. ("Thorne HealthTech" or "Thorne") (NASDAQ: THRN), a leader in developing innovative solutions for a personalized approach to health and well-being, today relaunched its Gut Health Test with the inclusion of its patent-pending Microbiome Wipe, a first-to-market approach to microbiome testing. Thorne's Microbiome Wipe revolutionizes the user experience of microbiome testing by eliminating inconvenient stool sampling that often leads users to either postpone the test or not take it at all.

Thorne Relaunches its Gut Health Test with the First-to-Market, User-Friendly Microbiome Wipe that Revolutionizes the Testing Experience

Thorne HealthTech (NASDAQ:THRN ) Q1 2022 Earnings Conference Call May 12, 2022 8:00 AM ET Company Participants Thomas Wilson - Vice President & Head of Investor Relations Paul Jacobson - Co-Founder & Chief Executive Officer Bryan Conley - Chief Financial Officer Michelle Crow - Chief Marketing Officer Thomas McKenna - Chief Operating Officer Conference Call Participants Elizabeth Anderson - Evercore ISI Sean Dodge - RBC Capital Markets Bryan Spillane - Bank of America Operator Hello, everyone and welcome to Thorne HealthTech, Inc. First Quarter 2022 Earnings Call. My name is Juan and I will be coordinating your call today.

Thorne HealthTech (THRN) CEO Paul Jacobson on Q1 2022 Results - Earnings Call Transcript

Reaffirms Full-Year 2022 Guidance NEW YORK , May 11, 2022 /PRNewswire/ -- Thorne HealthTech, Inc. ("Thorne HealthTech" or the "Company") (NASDAQ: THRN ), a leader in developing personalized, innovative solutions to help people live healthier, longer lives, today announced its financial results for the first quarter ended March 31, 2022. Highlights: Net sales grew 22.9% to $54.7 million, with direct-to-consumer ("DTC") sales growth of 33.0% Gross profit grew 29.6% to $30.1 million; gross margin increased 285 basis points to 55.1% Net income attributable to common stockholders of $5.0 million; adjusted EBITDA of $8.7 million Diluted earnings per share of $0.09; adjusted diluted earnings per share of $0.12 Full-year 2022 guidance reaffirmed for projected net sales of $240 million to $250 million; adjusted EBITDA of $30 million to $35 million; and adjusted EPS of $0.28 to $0.30 "Our solid first quarter performance was driven by robust growth across sales channels," said Paul Jacobson, Thorne HealthTech's chairman and CEO.

Thorne HealthTech Reports First Quarter 2022 Results

In a major research study, 4,000 participants collected their own blood samples to test for COVID-19 antibodies; 99.9% of samples received successfully processed NEW YORK , May 11, 2022 /PRNewswire/ -- Thorne HealthTech, Inc. ("Thorne HealthTech" or "Thorne") (NASDAQ: THRN), a leader in developing innovative solutions for a personalized approach to health and well-being and majority owner of Drawbridge Health, shared the results of a large-scale surveillance study conducted by the Medical Research Council (MRC) Epidemiology Unit, University of Cambridge, to assess the prevalence of previous infection with COVID-19 using remote blood samples collected with the novel patient-administered OneDraw™ Blood Collection Device. In addition to the ease of self-administration and near-pain-free experience for the user, 99.9% of the samples taken with the OneDraw device received by the laboratory were successfully processed, demonstrating the reliability of this approach in remote collection of blood samples.

Large-Scale Surveillance Study Confirms Reliability of the OneDraw™ Blood Collection Device In Remote Blood Sample Collection at Home

Increasing nutritional supplement portfolio aims to help individuals achieve lifelong wellness  PHOENIX , April 21, 2022 /PRNewswire/ --  Fullscript , the leading care delivery platform for integrative medicine, announced today that it has expanded its offerings to include Thorne HealthTech, Inc.  ("Thorne HealthTech" or "Thorne") (NASDAQ: THRN), a leader in developing innovative solutions for a personalized approach to health and well-being and one of the most trusted names in personalized, scientific wellness. Fullscript practitioners will now be able to order and recommend Thorne's industry-leading products, ultimately supporting the health and well-being of their patients.

Fullscript Adds Thorne HealthTech to Comprehensive Product Offering

COLORADO SPRINGS, Colo. , April 6, 2022 /PRNewswire/ -- USA Boxing and Thorne HealthTech, Inc. ("Thorne HealthTech" or "Thorne") (NASDAQ: THRN), a leader in developing innovative solutions for a personalized approach to health and well-being, announced today that Thorne will be USA Boxing's official performance nutrition partner for 2022.

USA Boxing Announces Partnership with Thorne HealthTech

Thorne is partnering with former professional football player Greg Olsen to highlight the importance of a proactive and personalized approach to well-being NEW YORK, March 28, 2022 /PRNewswire/ -- Thorne HealthTech, Inc. ("Thorne HealthTech" or "Thorne") (NASDAQ: THRN), a leader in developing innovative solutions for a personalized approach to health and well-being, today launched its Healthy Aging campaign, which challenges outdated views of aging in support of living longer, healthier lives. Through proactive and personalized knowledge, lifestyle changes, and nutritional supplementation, it is possible to minimize health risks and achieve healthy aging – feeling one's best at every age.

News for Thorne HealthTech Stock (THRN)